KCM
BIO icon

Kennedy Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Kennedy Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-85,066
Closed -$10.9M – 747
2014
Q1 		$10.9M Sell
85,066
-813
-0.9% -$104K 0.21% 171
2013
Q4 		$10.6M Buy
85,879
+582
+0.7% +$70.9K 0.2% 177
2013
Q3 		$10M Sell
85,297
-6,304
-7% -$743K 0.19% 177
2013
Q2 		$10.3M Buy
+91,601
New +$10.7M 0.21% 160

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kennedy Capital Management's BIO Position: Q2 2014 in Review

Kennedy Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2014, closing a stake of 85,066 shares — an estimated $10.9M sold.

Kennedy Capital Management first reported a position in BIO in Q2 2013 and held it in 4 quarters. The position peaked at $10.9M in Q1 2014. 204 funds tracked by Wall St. Rank hold BIO as of Q2 2014.

  • Kennedy Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2014 after selling out during the quarter.
  • Kennedy Capital Management sold 85,066 Bio-Rad Laboratories Class A shares in Q2 2014, an estimated $10.9M.
  • Kennedy Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 4 quarters.
  • Kennedy Capital Management's Bio-Rad Laboratories Class A position peaked at $10.9M in Q1 2014.
  • 204 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2014.

Based on Kennedy Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.